Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

357 results about "Small interfering RNA" patented technology

Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. It interferes with the expression of specific genes with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation.

Application of Wnt2 gene in buffalo ovarian granular cells

PendingCN119592628Apromote proliferationHigh expressionGenetically modified cellsNucleic acid vectorSignaling Pathway GeneGranular cell
The invention discloses application of a Wnt2 gene in buffalo ovarian granular cells, and belongs to the technical field of cell engineering and gene engineering. Wnt2 is taken as a research object, the Wnt2 overexpression vector or Wnt2 siRNA is transfected to the ovarian granulosa cells respectively by constructing the Wnt2 overexpression vector and synthesizing small interfering RNA (Wnt2 siRNA), then changes of signal channel gene mRNA and protein level related to ovarian granulosa cell apoptosis, proliferation and E2 and P4 secretion are detected, and finally phenotypic changes of the ovarian granulosa cells are detected. Results show that Wnt2 can inhibit apoptosis of ovarian granular cells and promote proliferation and E2 and P4 secretion. By exploring the application of the Wnt2 in the ovarian granular cells, the application has good application in researching an ovarian follicle atresia mechanism, initial estrus initiation and the like.
Owner:GUANGXI ZHUANG AUTONOMOUS REGION BUFFALO INST

ITGB1-siRNA lipid nanoparticle and application of ITGB1-siRNA lipid nanoparticle in anti-angiogenesis treatment

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to ITGB1-siRNA lipid nanoparticles and application of the ITGB1-siRNA lipid nanoparticles in anti-angiogenesis treatment. Specifically, the ITGB1-siRNA lipid nanoparticles are successfully prepared, the lipid nanoparticles are loaded with integrin beta1 small interfering RNA (ITGB1-siRNA), are modified with triptolide (TP) and are coupled with anti-Flt1 peptide, so that the lipid nanoparticles can target vascular endothelial cells (VEC) and pericytes of CNV, and a good treatment effect on the CNV is achieved. Therefore, the lipid nanoparticles researched and developed by the invention are expected to become a new choice for treating the CNV-related eye diseases, and have good practical application value.
Owner:SHANDONG FIRST MEDICAL UNIVERSITY FIRST AFFILIATED HOSPITAL (QIANFO MOUNTAIN HOSPITAL OF SHANDONG PROVINCE)

SiRNA for inhibiting expression of apolipoprotein C3

PendingCN119421952AMetabolism disorderDNA/RNA fragmentationDiseaseApolipoprotein C3
A siRNA that inhibits the expression of apolipoprotein C3 is provided. Provided are a small interfering RNA (siRNA) for inhibiting expression of APOC3 in a cell, a vector and a cell comprising a nucleotide encoding the same, and a method for treating a disease or symptom associated with expression of APOC3 in a subject using the siRNA, the vector or the cell.
Owner:SHANGHAI RONA THERAPEUTICS CO LTD

Double-stranded nucleotide compound for immune disease and use thereof

Provided are a small interfering RNA for inhibiting complement factor B (CFB) expression, and a use of the small interfering RNA in preparation of a drug for treatment of CFB expression-related diseases.
Owner:VISIRNA THERAPEUTICS (SUZHOU) CO LTD

Optimization method for single strand purity analysis of a sirna product

The present disclosure provides systems and methods for separating and characterizing oligonucleotides. Fixed dose combinations of small interfering RNAs can be subjected to denaturing ion pairing reverse phase liquid chromatography using optimal conditions to separate single RNA strands for purity analysis.
Owner:REGENERON PHARMACEUTICALS INC

Application of TRIM21 / OTUD4 in removal of SHBs / HBsAg

The invention discloses a medicine for removing SHBs / HBsAg protein and a preparation method thereof, and relates to the technical field of biology, the medicine comprises a recombinant plasmid of a TRIM21 gene and / or OTUD4 small interfering RNA; the preparation method comprises the following steps: synthesizing a TRIM21 gene and cloning the TRIM21 gene to an expression vector to obtain a recombinant plasmid; synthesizing a small interfering RNA (Ribonucleic Acid) of the OTUD4 gene; and transfecting the constructed recombinant plasmid or the synthesized small interfering RNA into liver cancer cells for expressing SHBs protein or HBV (Hepatitis B Virus). According to the present invention, the construction of the recombinant vector pcDNATM3.1 / myc-His (-) A-TRIM21-myc and the construction of the OTUD4 siRNA are constructed; overexpression of TRIM21 or knockout of OTUD4 can significantly inhibit expression of SHBs / HBsAg protein in liver cancer cells, expression of HBsAg and HBeAg protein secreted out of the cells and the HBV DNA level.
Owner:FUJIAN MEDICAL UNIV

Aptamer APT-Cai for targeting myocardial cells and biomolecular transport carrier

The invention provides a nucleic acid aptamer and a screening method thereof, the aptamer is of an oligonucleotide DNA structure, the nucleotide sequence of the nucleic acid aptamer is the nucleotide sequence of any DNA fragment as shown in SEQ ID NO: 1-9, and the nucleic acid aptamer can specifically target cardiac muscle cells (CMs). According to the invention, a new strategy can be provided for clinical treatment of cardiovascular diseases, and meanwhile, bioactive molecules such as microRNA (miRNA), small interfering RNA (small interfering RNA, siRNA), lipidosome, microspheres, microcapsules and the like can be carried to be used as an intracellular drug delivery tool.
Owner:CHINA THREE GORGES UNIV +1

Application of SFRP1 gene in buffalo ovarian granular cells

PendingCN119639815AHigh expressionavoid latchFermentationVector-based foreign material introductionGranular cellSignaling Pathway Gene
The invention discloses application of an SFRP1 gene in buffalo ovarian granular cells, and belongs to the technical field of cell engineering and gene engineering. According to the invention, SFRP1 is taken as a research object, an SFRP1 overexpression vector or siRNA-SFRP1 is respectively transfected to ovarian granular cells by constructing the SFRP1 overexpression vector and synthesizing small interfering RNA (siRNA-SFRP1), then changes of signal channel gene mRNA and protein level related to ovarian granular cell apoptosis, proliferation and E2 and P4 secretion are detected, and finally phenotypic changes of the ovarian granular cells are detected. Results show that the SFRP1 can inhibit apoptosis of ovarian granular cells and promote proliferation and E2 and P4 secretion. The application of the SFRP1 in the ovarian granular cells is explored, and the SFRP1 has good application in research of an ovarian follicle atresia mechanism, initial estrus initiation and the like.
Owner:GUANGXI ZHUANG AUTONOMOUS REGION BUFFALO INST

Method for detecting target nucleic acids using RNA blocking molecules

PendingCN119855920AMicrobiological testing/measurementPiwi-interacting RNAIn situ hybridisation
Embodiments of the present disclosure include compositions and methods for conducting in situ hybridization reactions. In particular, the disclosure provides RNA blocking molecules that enhance the detection of target RNA molecules (e.g., mRNA molecules, micro RNA (miRNA) molecules, small non-coding RNA (sncRNA) molecules, PIWI interacting RNA (piRNA) molecules, and / or small interfering RNA (siRNA) molecules) by reducing the binding of a target probe to non-target RNA molecules in a sample.
Owner:ADVANCED CELL DIAGNOSTICS INC

Nanometer hydrogel preparation for packaging small interfering RNA and preparation method of nanometer hydrogel preparation

The invention discloses a nano hydrogel preparation for packaging small interfering RNA (Ribonucleic Acid) and a preparation method, and belongs to the technical field of nano pesticides. Gold nanoparticles and dendritic mesoporous silica nanoparticles are used as composite carriers to load small interfering RNA, then a pectin solution is used for packaging, and the nano hydrogel preparation is prepared, so that the adhesion of a medicament is greatly enhanced, and rapid permeation and targeted delivery of the medicament are realized.
Owner:SHANDONG AGRICULTURAL UNIVERSITY +1

Compositions and methods for regulating mapt

The disclosure relates to small interfering RNA (siRNA) molecules targeting MAPT and adeno-associated viral (AAV) particles encoding the same for treating tauopathies.
Owner:VOYAGER THERAPEUTICS INC

Application of small interfering RNA (Ribonucleic Acid) targeting Zyx gene

The invention belongs to the technical field of biological medicines, and particularly relates to application of small interfering RNA (Ribonucleic Acid) of a targeted Zyx gene. The invention provides siRNA (small interfering Ribonucleic Acid) of a targeted Zyx gene, and further provides application of the siRNA in prevention and treatment of fibrosis interstitial lung diseases. Experimental data prove that in a mouse bleomycin model, siRNA of a targeted Zyx gene can effectively improve the survival rate of a sick mouse, alveolar wall thickening, lung substantive thickening and inflammatory cell infiltration of a Zyx knock-down group are not obvious, and pathological damage caused by bleomycin is effectively relieved through knock-down of the Zyx gene; collagen fiber deposition of a Zyx knock-down group is reduced, and the transcription level of fibrosis-related genes is obviously reduced.
Owner:WOMEN & CHILDRENS MEDICAL CENTER AFFILIATED WITH GUANGZHOU MEDICAL UNIVERSITY

RNAi Agents for Inhibiting Expression of Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Pharmaceutical Compositions Thereof, and Methods of Use

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).
Owner:ARROWHEAD PHARMACEUTICALS INC

Application of CNPY2 as new target in diagnosis and treatment of diabetic nephropathy

The invention belongs to the technical field of biological medicine, and particularly relates to application of CNPY2 as a new target in diagnosis and treatment of diabetic nephropathy. The invention provides a biomarker CNPY2 gene or CNPY2 protein for auxiliary diagnosis of diabetic nephropathy for the first time. The expression of the CNPY2 in the renal tubule of a DN patient is up-regulated, the expression of the CNPY2 in the renal tubule of a db / db mouse is up-regulated, and the expression of the CNPY2 in an HK-2 cell subjected to in-vitro high-glucose culture is up-regulated; therefore, the CNPY2 can be used as an auxiliary diagnosis index of the diabetic nephropathy for auxiliary diagnosis of the diabetic nephropathy. The invention also provides a kit for auxiliary diagnosis of diabetic nephropathy. The kit contains a detection reagent of the CNPY2 gene or the coded protein. The invention also finds that by knocking down the adeno-associated virus through the CNPY2 and inhibiting the expression or activity of the CNPY2 through the specific small interfering RNA of the adeno-associated virus, the pathological injury of the renal tubules of db / db mice can be obviously improved, the integrity of MAM in the renal tubule epithelial cells is improved, and the ferroptosis, ERS and mitochondrial injury of the renal tubule epithelial cells are alleviated; therefore, the CNPY2 can be used as a drug, a drug target or a target gene in gene therapy, and is applied to prevention, alleviation or / and treatment of diabetic nephropathy.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

Bionic nano radiotherapy sensitizer as well as preparation method and application thereof

The invention discloses a bionic nano radiotherapy sensitizer as well as a preparation method and application thereof, and belongs to the field of tumor treatment. The bionic nano radiotherapy sensitizer comprises a radiotherapy sensitizing material and a nano-material, a small interfering RNA; the tumor cell coating wraps the radiotherapy sensitization material and the small interfering RNA; the near-infrared fluorescent dye is modified on the outer surface of the tumor cell coating. The sensitizer disclosed by the invention can be used for specifically recognizing homotype tumors, delivering the radiotherapy sensitizer after accurate targeting of the tumors, effectively enhancing intracellular radioactive ray energy deposition, improving the hypoxia state of tumor cells, sensitizing radiotherapy, silencing expression of target genes of the tumor cells and inhibiting negative immunoregulation, so that the anti-tumor immune response of effector T cells is enhanced, and the radiotherapy effect is improved. In addition, on the basis of the near-infrared fluorescent material, the in-vivo delivery process of the bionic nano radiotherapy sensitizer can be traced.
Owner:GENERAL HOSPITAL OF NUCLEAR IND

Methods of designing conditional-activatable small interfering RNA sensors

Provided herein include methods, systems, and compositions for designing a sensor nucleic acid strand of a conditionally activatable small interfering RNA (siRNA) complex as well as the siRNA complexes generated using the method herein described and the component strands. The siRNA complex can be conditionally activated upon a complementary binding to an input nucleic acid strand (e.g. a mRNA of a biomarker gene specific to a target cell) through a sequence in a sensor nucleic acid strand of the nucleic acid complex. The activated nucleic acid complex can release a potent RNAi duplex formed by a core nucleic acid strand and a passenger nucleic acid strand, which can specifically inhibit a target RNA.
Owner:SWITCH THERAPEUTICS INC

Double-stranded nucleotide compound for metabolic diseases and use thereof

PCT designated stage expiredWO2024245151A1Organic active ingredientsMetabolism disorderDiseaseNucleotide
The present invention relates to the technical field of genetic engineering, and in particular, to a small interfering RNA for inhibiting the expression of diacylglycerol acyltransferase-2 (DGAT-2) and the use thereof in the preparation of a drug for treating diseases related to the expression of DGAT2.
Owner:VISIRNA THERAPEUTICS (SUZHOU) CO LTD

Application of kynurenase protein inhibitor in preparation of medicine for treating radioactive intestinal injury

The invention discloses application of a kynurenase protein inhibitor in preparation of a medicine for treating radioactive intestinal injury, and belongs to the technical field of biological medicine. The invention discloses the interaction between the kynurenase protein KYNU and the radioactive intestinal injury for the first time, and through gene knockout and expression research of an MAPK signal channel, it is clear that the radioactive intestinal injury can be effectively relieved by inhibiting the expression of the KYNU. Based on the research results, the invention emphatically puts forward that carbidopa can be used as a kynureninase protein KYNU inhibitor and plays a key role in radioactive intestinal injury, so that a new medicine application for treating radioactive intestinal injury is provided aiming at KYNU inhibition; the invention also provides a small interfering RNA (siRNA) for inhibiting the expression of kynureninase protein KYNU for the first time, the KYNU is knocked down, so that the cell proliferation after irradiation can be increased, the cell apoptosis and oxidative stress can be reduced, and KYNU knock-down has a protective effect on radioactive intestinal injury.
Owner:YANGZHOU FIRST PEOPLES HOSPITAL

SiRNA molecule for regulating and controlling activity of PCSK9 gene

Provided are a small interfering RNA (siRNA) for inhibiting expression of proprotein convertase subtilisin / kexin type 9 (PCSK9) in a cell, a vector and a cell comprising a nucleotide encoding the same, and a method for treating a disease or symptom associated with PCSK9 expression in a subject using the siRNA, the vector or the cell.
Owner:SHANGHAI RONA THERAPEUTICS CO LTD

Targeted inhibitor of Mmrn1, inhibition method and application

The invention relates to the field of biological medicine, in particular to an Mmrn1 targeted inhibitor, an inhibition method and application. According to the application disclosed by the invention, firstly, the relationship between the expression of the MMRN1 gene in the acute myelogenous leukemia (AML) and the regulation and control of a'siglecan-siglecc 'axis is creatively disclosed. Therefore, the invention firstly provides a small interfering RNA (Ribonucleic Acid) targeting the Mmrn1 in the leukemia stem cell, and an application of the small interfering RNA in preparation of a'sialic acid glycan-siglecc 'axis immune checkpoint inhibitor.
Owner:CHONGQING MEDICAL UNIVERSITY

A targeting ligand

The present disclosure relates to the field of genetic engineering technology, and more specifically, to a targeting ligand. The targeting ligand provided herein forms a siRNA conjugate with a specific small interfering RNA sequence, which targets ANGPTL3 and degrades ANGPTL3 gene transcripts in cells, thereby reducing ANGPTL3 protein expression. Therefore, the siRNA conjugate formed with the targeting ligand provided herein can be used to prevent and / or treat dyslipidemia.
Owner:YITENG HOLDINGS ONE PERSON CO LTD +1

Construction of engineered erythrocyte extracellular vesicle drug delivery system and application of engineered erythrocyte extracellular vesicle drug delivery system in leukemia

The invention belongs to the technical field of biological medicine, and particularly relates to construction of an engineered erythrocyte extracellular vesicle drug delivery system and application of the engineered erythrocyte extracellular vesicle drug delivery system in leukemia. The invention firstly provides a leukemia cell targeting composite immunomodulator, which is composed of a drug carrying system prepared from erythrocyte extracellular vesicles and a content, the medicine carrying system comprises erythrocyte extracellular vesicles and targeting parts connected to the erythrocyte extracellular vesicles; the content is a small molecule drug and a small interfering RNA (Ribonucleic Acid) synergistic substance. The composite immunomodulator has a composite effect of inducing leukemia cell immunogen cell death and immune activation.
Owner:FULING HOSPITAL AFFILIATED TO CHONGQING UNIV

RNA interference mediated therapy for neoplastic diseases

PCT designated stage expiredWO2025003985A1Organic active ingredientsAntineoplastic agentsDiseaseGenetics
A double- stranded small interfering RNA (siRNA) having a length of at least 19 nucleotides, targeting an exon of Trim28 gene mmRRNNAA (gene ID: ENST000000253024.10), wherein the exon is selected from the group consisting of exon 3, exon 4, exon 6 and exon 12, and wherein the double-stranded siRNA is capable of inhibiting TRIM28 protein, uusseess and compositions thereof.
Owner:UNIV DEGLI STUDI DEL PIEMONTE ORIENTALEAMEDEO AVOGADRO +1

SiRNA of pyroptosis-related inflammatory response gene and application thereof

The application provides a group of small interfering RNAs (siRNAs) targeting pyroptosis-related inflammatory reaction genes and application thereof. The pyroptosis-related inflammatory reaction genes include IL1A, IL1B, IL6, HMGB1, S100A8, S100A9 and BACH1. The application designs and synthesizes specific siRNA sequences for the above genes, and verifies that the siRNAs can efficiently and specifically inhibit the mRNA expression level of the corresponding genes through cell transfection and real-time fluorescent quantitative PCR. The application also provides a composition containing the siRNAs, a pharmaceutical composition and application thereof in the preparation of a drug for treating diseases mediated by pyroptosis-related inflammatory reaction genes (especially inflammatory diseases). The siRNAs and the composition thereof provide a new effective strategy for treating diseases related to excessive activation of pyroptosis-related inflammatory reactions, and have a wide application prospect.
Owner:SHANGHAI GENEPHARMA CO LTD

SiRNA capable of knocking down Pr18a9 gene expression and application thereof

The invention discloses siRNA capable of knocking down Pr18a9 gene expression and application of the siRNA, and relates to the technical field of biological medicine. The invention provides a positive-sense strand sequence and an antisense strand sequence of the siRNA, and the siRNA is used for preparing a preparation for promoting Schwann cell survival. According to the invention, the Prl8a9 gene of SCs is knocked down by virtue of a small interfering RNA technology; by improving the proliferation and migration capabilities of the Schwann cells, the apoptosis rate of the Schwann cells is reduced, and the survival rate of the Schwann cells is further improved. Meanwhile, a transcriptome sequencing technology is applied, key genes and pathways of Schwann cells treated by siPr18a9 are deeply excavated, and a theoretical support is provided for research on a repair mechanism after peripheral nerve injury.
Owner:CHENGDE MEDICAL UNIV

GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY

Provided herein is a composition comprising GalNAc moiety that can be conjugated to oligonucleotide.The oligonucleotide can be small interfering RNA or antisense oligonucleotide.Also provided herein is a method of treatment comprising administering the composition to a subject.
Owner:EMPIRICO INC